Did you know that colon cancer, also called colorectal cancer (CRC), is a big health issue in the UK? It's the third most common cancer and the second leading cause of cancer deaths. So, how do we better diagnose it in people who have symptoms? A new model called COLOFIT has been created to help wi
Cancer control is a big deal for health systems today. But how do we tackle it effectively? That's where system dynamics modeling (SDM) comes in. This study dives into how SDM is used to understand and combat cancer. Researchers checked out a bunch of studies to see how well SDM is doing its job. F
Scientists have been working on a new way to make treating pancreatic cancer safer and more effective. They're using something called nanoliposomes to carry a special antibody called CD40a. These tiny carriers have a clever trick: they stick to the tumor's surface when they sense a particular enviro
Scientists have found a clever way to make quercetin, a naturally occurring compound, more effective against triple-negative breast cancer (TNBC). They created special liposomes, tiny fat particles, that can target and release quercetin more precisely. These liposomes are coated with a material call
Imagine you're battling advanced biliary tract cancer (ABTC), and your doctors suggest a mix of drugs: nivolumab, modified gemcitabine, and S-1. This combo showed promise in a past trial, but PD-L1 levels didn't tell us much about how well it would work. So, scientists looked at another marker, LAG-
You might not think about it, but the time of day you get your cancer treatment could make a difference. Scientists have been looking into how our body's internal clock, called the circadian rhythm, affects how well cancer drugs work. One type of drug, called immune checkpoint inhibitors (ICIs), has
Immune treatments, or immune checkpoint inhibitors (ICIs), are game-changers for some people with far-advanced solid tumors. But when it comes to biliary tract cancer (BTC), doctors are still figuring out who gets the most benefit from these treatments. A recent trial focused on pembrolizumab, an IC
Biliary tract cancers, like cholangiocarcinoma and gallbladder cancer, are growing more common worldwide, and most patients get diagnosed when the disease has already advanced, leading to a grim outlook. Recently, combining immune checkpoint inhibitors, such as durvalumab and pembrolizumab, with the
Immune-checkpoint inhibitors (ICIs) have emerged as a powerful tool in the fight against advanced squamous cell lung cancer (LUSC). These drugs offer a glimmer of hope for patients who haven't found success with other treatments. But it's not a one-size-fits-all solution—some patients don't respond
Ever noticed how people with early breast cancer often get quicker treatments? That's what scientists already know. But what about those with metastatic breast cancer (MBC), where it spreads to other parts of the body? Not much is known about why they face delays in getting care. This study is chang
